ABSTRACT
OBJECTIVES: Coronavirus disease 2019 has been reported to be a prothrombotic condition; however, multicenter data comparing this with other viral pneumonias in those requiring extracorporeal membrane oxygenation are lacking. We conducted a multicenter study using whole-body CT to examine the prevalence, severity, and nature of vascular complications in coronavirus disease 2019 in comparison with patients with other viral pneumonias. DESIGN: We analyzed whole-body CT scans for the presence of vascular thrombosis (defined as pulmonary artery thrombus, venous thrombus, systemic arterial thrombus, or end-organ infarct). The severity, distribution, and morphology of pulmonary artery thrombus were characterized. Competing risk cumulative incidence analysis was used to compare survival with discharge. SETTING: Three centers of the English national extracorporeal membrane oxygenation service. PATIENTS: Consecutive patients admitted with either coronavirus disease 2019 or noncoronavirus disease 2019 viral pneumonia admitted from January 2019. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: One-hundred thirty-six patients (45.2 ± 10.6 yr old, 39/146 [27%] female) requiring extracorporeal membrane oxygenation support underwent whole-body CT scans at admission. Of these, 86 had coronavirus disease 2019 pneumonia, and 50 had noncoronavirus disease 2019 viral pneumonia. Vascular thrombosis was seen more often in patients with coronavirus disease 2019 (odds ratio, 12.9 [95% CI 4.5-36.8]). In those with coronavirus disease 2019, 57 (73%) demonstrated pulmonary artery thrombus or pulmonary perfusion defects. Eighty-two percent of thrombus exhibited emboli-like morphology. The location of pulmonary artery thrombus and parenchymal perfusion defects was only concordant in 30% of cases. The risk of mortality was higher in those with coronavirus disease 2019 compared with noncoronavirus disease 2019 pneumonia (χ2 = 3.94; p = 0.047). Mortality was no different in coronavirus disease 2019 patients with or without vascular thrombosis (χ2 = 0.44; p = 0.51). CONCLUSIONS: In patients who received extracorporeal membrane oxygenation, coronavirus disease 2019 is associated with a higher prevalence of vascular thrombosis compared with noncoronavirus disease viral pneumonias. The pattern of pulmonary vascular changes suggests concurrent embolic disease and small vessel disease. Despite this, vascular thrombosis was not linked to poorer short-term prognosis in those with coronavirus disease 2019.
Subject(s)
COVID-19/complications , Extracorporeal Membrane Oxygenation , Pneumonia, Viral/complications , Thrombosis/etiology , Adult , COVID-19/therapy , Female , Humans , Male , Middle Aged , Pneumonia, Viral/therapy , Prognosis , Thrombosis/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Common variable immunodeficiency (CVID) is the most frequent clinically relevant primary immunodeficiency and shows enormous heterogeneity in clinical presentation. Despite clinical immunodeficiency, opportunistic infections are not a typical manifestation of CVID. A retrospective study of 32 patients followed up for 335 patient-years was performed to determine the frequency of cytomegalovirus (CMV) disease. Symptomatic CMV infection was documented in 3 CVID patients. Patients No. 1 and 2 suffered from CMV pneumonia, with complications due to atypical mycobacteriosis in patient No. 1. Patient No. 3 suffered from CMV enteritis. A history of cancer and chronic hepatitis C infection (patient No. 1), immunosuppressive therapy for interstitial lung disease (patient No. 2) and serious enteropathy complicated with malnutrition (patient No. 3) may have contributed to the complications despite only mild abnormalities in T-cell subpopulations. The direct detection of CMV in bronchoalveolar lavage, stool or tissue samples was the most beneficial diagnostic laboratory method, whereas the detection of CMV DNA in blood did not produce positive results. Adequate treatment of CMV disease led to significant clinical improvement in all 3 patients. The frequency of CMV disease appears to be higher than previously described. In our experience, the probability of opportunistic infections in CVID patients increases with secondary comorbidities and their management.
Subject(s)
Common Variable Immunodeficiency/diagnosis , Cytomegalovirus Infections/diagnosis , DNA, Viral/isolation & purification , Enteritis/diagnosis , Mycobacterium Infections, Nontuberculous/diagnosis , Pneumonia, Viral/diagnosis , Bronchoalveolar Lavage Fluid/virology , Common Variable Immunodeficiency/complications , Common Variable Immunodeficiency/pathology , Common Variable Immunodeficiency/virology , Cytomegalovirus , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/pathology , Cytomegalovirus Infections/virology , Enteritis/complications , Enteritis/pathology , Enteritis/virology , Feces/virology , Female , Humans , Middle Aged , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium Infections, Nontuberculous/pathology , Mycobacterium Infections, Nontuberculous/virology , Pneumonia, Viral/complications , Pneumonia, Viral/pathology , Pneumonia, Viral/virologyABSTRACT
Bleeding management in cardiac surgery could be a great challenge for the surgeon and a life-threatening moment for the patient. Despite the fact that recombinant activated factor VII is now widely accepted as a useful adjunct in the management of postcardiotomy coagulopathy, its use in the course of recent thromboembolic event is rarely described. We hereby present a case of rescue recombinant activated factor VII administration to manage a severe coagulation disorder during surgical pulmonary embolectomy performed under cardiopulmonary bypass.
Subject(s)
Blood Coagulation Disorders/complications , Blood Coagulation Disorders/drug therapy , Embolectomy/adverse effects , Factor VII/administration & dosage , Postoperative Hemorrhage/etiology , Postoperative Hemorrhage/prevention & control , Pulmonary Embolism/surgery , Coagulants/administration & dosage , Factor VII/genetics , Humans , Male , Middle Aged , Pulmonary Embolism/complications , Recombinant Proteins/adverse effects , Treatment OutcomeSubject(s)
Cytapheresis/methods , Macular Degeneration/therapy , Retinal Detachment/therapy , Retinal Drusen/therapy , Retinal Pigment Epithelium/pathology , Follow-Up Studies , Humans , Macular Degeneration/complications , Macular Degeneration/diagnosis , Middle Aged , Retinal Detachment/diagnosis , Retinal Detachment/etiology , Retinal Drusen/complications , Retinal Drusen/diagnosis , Treatment OutcomeSubject(s)
Antibodies, Antineutrophil Cytoplasmic/blood , Antibodies, Monoclonal, Humanized/therapeutic use , Glomerulosclerosis, Focal Segmental/complications , Immunoglobulin G/blood , Mediastinal Diseases/complications , Spondylitis, Ankylosing/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Glomerulosclerosis, Focal Segmental/diagnosis , Glomerulosclerosis, Focal Segmental/immunology , Humans , Male , Mediastinal Diseases/diagnosis , Mediastinal Diseases/immunology , Middle Aged , Spondylitis, Ankylosing/complicationsABSTRACT
Bio-degradable stents are be made of different synthetic polymers (like polylactide or polyglycolide) or their co-polymers (polydioxanone). They can be used for treating benign stenoses of the small and large intestine, particularly in Crohn's disease. Endoscopic introduction of bio-degradable stents into small and large intestinal stenoses is feasible and relatively simple. Initial results are encouraging and the complication rate is low. However, there are still some difficulties that need to be overcome. The rate of early stent migration is still rather high (up to one third of patients). This might be solved by changes in the shape or rigidity of the stents as well as by further improvement in the design. Proof of long-term efficacy and safety requires further studies.
Subject(s)
Biocompatible Materials , Crohn Disease/complications , Intestinal Obstruction/surgery , Stents , Absorbable Implants , Adult , Animals , Crohn Disease/surgery , Endoscopy, Gastrointestinal , Female , Humans , Intestinal Obstruction/etiology , Male , PolymersABSTRACT
The authors present a case of a 4-year-old girl with an orbital floor fracture. During surgery absorbable collagenous mesh (Pelvicol) was placed between the bone wall and the orbital periosteum. Pelvicol was selected as a natural xenogeneic tissue (porcine dermis) ready for first use in the reconstruction of the orbital floor fracture. The patient has fully recovered without any symptoms.